SIRPA and neoplasm: SIRPα could also target paxillin and cofilin while inhibiting phagocytosis which is mediated by additional phagocytic receptors such as FcγR (Oldenborg et al., 2001) and during the phagocytosis of particles other than myelin-debris such as aging red blood cells (Oldenborg et al., 2000) and tumor cells (Chao et al., 2012; Kim et al., 2012).